Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro (Q37780212)

23 August 2017

1 reference

title

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro (English)

1 reference

23 August 2017

3

Jerold S Harmatz

1 reference

23 August 2017

1

David J Greenblatt

1 reference

23 August 2017

5

Lisa L von Moltke

1 reference

PubMed ID

20712450

23 August 2017

Karthik Venkatakrishnan

series ordinal

2

object named as

Karthik Venkatakrishnan

1 reference

23 August 2017

Sarah J Parent

4

1 reference

PubMed ID

20712450

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

40

1 reference

23 August 2017

10

1 reference

23 August 2017

713-720

1 reference

Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise

23 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

CYP3A4 drug interactions: correlation of 10 in vitro probe substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Heterotropic cooperativity in oxidation mediated by cytochrome p450.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Inhibition and induction of human cytochrome P450 enzymes: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Studies on the Interactions between Drug and Estrogen. II. On the Inhibitory Effect of 29 Drugs Reported to Induce Gynecomastia on the Oxidation of Estradiol at C-2 or C-17

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro and in vivo drug interactions involving human CYP3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2010.506224

10.3109/00498254.2010.506224

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20712450